Lupin Mira-S 25 Tablet is a combination pharmaceutical formulation containing Mirabegron 25 mg and Solifenacin 5 mg, indicated for the management of overactive bladder (OAB) with symptoms of urgency, frequency, and urge urinary incontinence. Mirabegron, a selective β3-adrenoceptor agonist, acts by relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, thereby increasing bladder capacity without compromising voiding function. Solifenacin, an antimuscarinic agent, exerts its therapeutic effect by selectively inhibiting the M3 muscarinic receptors in the bladder, reducing involuntary detrusor contractions and improving urinary continence. The combination of these two agents provides a complementary mechanism of action, enhancing efficacy in symptom control while potentially minimizing adverse effects associated with higher doses of either component alone. Lupin Mira-S 25 is typically prescribed when monotherapy has been insufficient or when combination therapy is deemed appropriate by the clinician. Patients should be monitored for common side effects such as dry mouth, constipation, hypertension, and urinary retention. Caution is advised in patients with severe uncontrolled hypertension, urinary retention, or significant hepatic or renal impairment. This medication should be used under medical supervision, with dosage adjustments based on therapeutic response and tolerability.